1. Netherlands Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
argenx SE

argenx SE

ARGX.BR
argenx SEBE flagEuronext Brussels
787.60
EUR
-12.20
- -
48.74BMarket Cap
argenx SE
ARGX.BR
(Euronext Brussels)

Recent

price

787.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.09
0.14
0.24
0.6
0.48
0.82
1.78
0.68
2.03
0.91
9.74
7.55
21.45
36.59
67.76
75.11
Revenue per Share
- -
-0.29
-0.82
-0.54
-1.66
-1.06
-1.19
-1.37
-2.12
-4.69
-13.4
-7.99
-13.05
-5.16
13.92
21.08
23.99
Basic EPS, GAAP
- -
-0.27
-0.71
-0.59
-0.87
-0.99
0.54
-1.8
-1.73
2.72
-8.89
-14.26
-17.78
-8.12
-2.52
9.36
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.77
-1.6
-2.2
-5.51
-3.44
-3.94
-4.75
-5.28
-9.79
-21.72
-27.29
-38.67
-41.94
-26.14
-4.44
- -
Book Value per Share
- -
1.78
1.06
1.91
8.06
2.59
3.54
16.81
17.12
29.4
33.18
46.26
48.52
69.48
88.83
115.03
- -
Tangible Book Value per Share
- -
16
16
16
8
16
19
25
36
39
45
51
54
57
60
61
62
Basic Weighted Avg Shares
- -
1
2
4
5
7
15
44
25
78
41
497
411
1,226
2,190
4,153
4,661
Sales/Revenue/Turnover
- -
-323.64
-608.78
-232.69
-286.02
-227.68
-145.56
-62.97
-381.01
-255.04
-1,165.21
-72.37
-176.24
-34.3
-0.81
25.39
28.05
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
1
2
4
6
104
111
18
28
- -
Depreciation Expense
- -
-4
-13
-8
-13
-17
-22
-34
-76
-181
-608
-408
-710
-295
833
1,292
1,489
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.91
Effective Tax Rate (%)
- -
-308
-587.4
-229.03
-274.6
-223.4
-145.27
-77.1
-310.22
-230.95
-1,475.29
-82.1
-172.76
-24.06
38.03
31.11
31.94
Profit Margin (%)
10
28
16
29
60
39
73
411
609
1,363
1,729
2,242
2,472
3,701
4,213
5,579
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
5
6
8
9
15
33
36
- -
LT Debt
10
28
17
30
61
41
67
414
616
1,180
1,674
2,534
2,814
4,098
5,498
7,323
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-73.21
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
11
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
36
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
62
- -
Market Capitalization
37,639
43,713
38,525

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
6,899
- -
Cash, Cash Equivalents & STI
- -
4,440
- -
Accounts Receivable, Net
- -
1,490
- -
Inventories
- -
474
- -
Total Current Liabilities
- -
1,320
- -
Payables & Accruals
- -
695
- -
ST Debt
- -
11
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
94.21%
35.08%
33.19%
Free Cash Flow
-189.63%
-97.19%
-479.69%
Net Income, GAAP
23.92%
-68.95%
55.1%
Sales/Revenue/Turnover
187.2%
291.02%
89.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
401
478
573
738
2,190
2025
790
948
1,127
1,288
4,153
2026
1,298
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.04
- -
1.52
- -
13.92
2025
2.77
- -
- -
- -
21.08
2026
5.9
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Ainos, Inc. (AIMDW)
Futura Medical plc (FUM.L)
NeuroScientific Biopharmaceuticals Limited (NSB.AX)
Oxford BioDynamics Plc (OXBOF)
NeonMind Biosciences Inc. (NMDBF)
4basebio PLC (4BB.L)
Business
argenx SE argenx SE is a commercial-stage global immunology company that develops differentiated antibody-based therapies for severe autoimmune diseases; it offers VYVGART (efgartigimod), a first-in-class FcRn blocker approved in more than 30 countries including the US, EU, UK, Japan, Israel, China and Australia for generalized myasthenia gravis (gMG) in both intravenous and subcutaneous formulations (VYVGART SC), for chronic inflammatory demyelinating polyneuropathy (CIDP) in the US, China and Japan (as VYVDURA), and for immune thrombocytopenia (ITP) in Japan (as VYVDURA); it advances empasiprubart, a C2 complement inhibitor in Phase 3 for multiple autoimmune indications including multifocal motor neuropathy; and it progresses earlier-stage candidates such as ARGX-119 (MuSK agonist) in proof-of-concept for congenital myasthenic syndrome, amyotrophic lateral sclerosis and spinal muscular atrophy, alongside preclinical assets ARGX-213 (FcRn), ARGX-121 (IgA), ARGX-220 and ARGX-109 (IL-6). The company leverages its Immunology Innovation Program (IIP) and proprietary technologies including SIMPLE ANTIBODY platform, NHANCE, ABDEG, POTELLIGENT and DHS mutations to engineer antibodies; it operates through subsidiaries in the US (Boston), Belgium (Zwijnaarde), Japan (Tokyo), France, UK, Netherlands, Switzerland, Germany, Canada, Italy, Spain, Portugal, Australia and Austria; founded in 2008 and headquartered in Amsterdam, Netherlands, argenx SE conducts R&D primarily in Belgium and commercializes products globally targeting underserved patients in immunology. Recent developments include expansion of its ENHANZE license agreement with Halozyme in September 2024 by nominating four additional targets for a total of six including FcRn and C2 to enable subcutaneous formulations; a new manufacturing partnership expansion with FUJIFILM featuring a site in North Carolina; topline results from the registrational EMPASSION Phase 3 study in multifocal motor neuropathy for empasiprubart; plans for five registrational readouts in 2026 and submission of a supplemental BLA for seronegative gMG by end-2025; and combined 2025 R&D and SG&A guidance of approximately $2.5 billion.